唑来膦酸治疗接受辅助芳香化酶抑制剂治疗的原发性乳腺癌女性的骨质疏松症和骨质疏松症。
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
机构信息
Mayo Clinic Florida, Jacksonville, FL 32224, USA.
出版信息
Breast. 2010 Apr;19(2):92-6. doi: 10.1016/j.breast.2009.12.001. Epub 2010 Jan 15.
Abstract
BACKGROUND
Postmenopausal women with osteoporosis/osteopenia are at increased risk of fracture. Aromatase inhibitors further increase bone loss in these patients. This study evaluates whether zoledronic acid prevents the bone loss expected when these patients initiate letrozole.
PATIENTS AND METHODS
Postmenopausal women with estrogen and/or progesterone receptor-positive breast cancer and a bone mineral density (BMD) T-score <-2.0 were given letrozole 2.5mg/vitamin D 400 international units daily, calcium 500mg twice daily, and 4mg zoledronic acid every 6 months. The BMD was assessed at baseline and 1 year. The primary endpoint was the mean change in lumbar spine (LS) BMD at 1 year.
RESULTS
Forty-six patients completed 1 year of treatment. LS BMD increased by 2.66% (p=0.01), femoral neck (FN) by 4.81% (p=0.01), and any measured endpoint by 4.55% (p=0.0052).
CONCLUSIONS
Zoledronic acid prevents bone loss in postmenopausal women with osteoporosis/osteopenia starting letrozole and is associated with improvements in BMD.
摘要
背景
患有骨质疏松症/骨量减少的绝经后妇女骨折风险增加。芳香化酶抑制剂会进一步增加这些患者的骨质流失。本研究评估唑来膦酸是否可以预防开始使用来曲唑时这些患者预期的骨质流失。
患者和方法
患有雌激素和/或孕激素受体阳性乳腺癌且骨密度（BMD）T 评分<-2.0 的绝经后妇女每日给予来曲唑 2.5mg/维生素 D 400 国际单位、钙 500mg 每日两次和唑来膦酸 4mg，每 6 个月一次。在基线和 1 年时评估 BMD。主要终点是 1 年时腰椎（LS）BMD 的平均变化。
结果
46 例患者完成了 1 年的治疗。LS BMD 增加了 2.66%（p=0.01），股骨颈（FN）增加了 4.81%（p=0.01），任何测量终点都增加了 4.55%（p=0.0052）。
结论
唑来膦酸可预防开始使用来曲唑的骨质疏松/骨量减少绝经后妇女的骨质流失，并与 BMD 的改善相关。
相似文献
1
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.唑来膦酸治疗接受辅助芳香化酶抑制剂治疗的原发性乳腺癌女性的骨质疏松症和骨质疏松症。
Breast. 2010 Apr;19(2):92-6. doi: 10.1016/j.breast.2009.12.001. Epub 2010 Jan 15.
2
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.唑来膦酸用于接受辅助芳香化酶抑制剂治疗的原发性乳腺癌女性骨质疏松症和骨质减少症的治疗：5年随访
Support Care Cancer. 2016 Mar;24(3):1219-26. doi: 10.1007/s00520-015-2915-2. Epub 2015 Aug 23.
3
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.唑来膦酸立即给药与延迟给药对在他莫昔芬治疗后开始来曲唑治疗的绝经后乳腺癌女性预防骨质流失的作用——N03CC研究
Breast Cancer Res Treat. 2009 Oct;117(3):603-9. doi: 10.1007/s10549-009-0332-2. Epub 2009 Feb 12.
4
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.唑来膦酸即刻给药可减少早期乳腺癌绝经后妇女芳香酶抑制剂相关的骨丢失：E-ZO-FAST 试验 12 个月分析。
Clin Breast Cancer. 2012 Feb;12(1):40-8. doi: 10.1016/j.clbc.2011.08.002. Epub 2011 Oct 19.
5
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.唑来膦酸用于预防接受辅助来曲唑治疗的绝经后早期乳腺癌妇女芳香化酶抑制剂相关骨质流失的综合分析。
Oncologist. 2008 May;13(5):503-14. doi: 10.1634/theoncologist.2007-0206.
6
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.Z-FAST 试验的最终 5 年结果：接受来曲唑治疗的绝经后乳腺癌患者使用唑来膦酸辅助治疗可维持骨量。
Cancer. 2012 Mar 1;118(5):1192-201. doi: 10.1002/cncr.26313. Epub 2011 Oct 10.
7
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.绝经前早期乳腺癌患者辅助内分泌治疗联合唑来膦酸：ABCSG-12骨密度亚研究的5年随访
Lancet Oncol. 2008 Sep;9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19.
8
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.唑来膦酸对接受辅助来曲唑治疗的绝经后早期乳腺癌女性芳香化酶抑制剂相关骨质流失的有效抑制作用：ZO-FAST研究结果
Cancer. 2008 Mar 1;112(5):1001-10. doi: 10.1002/cncr.23259.
9
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.唑来膦酸可有效预防接受辅助来曲唑治疗的绝经后早期乳腺癌女性患者出现芳香化酶抑制剂相关的骨质流失：Z-FAST研究36个月随访结果
Clin Breast Cancer. 2009 May;9(2):77-85. doi: 10.3816/CBC.2009.n.015.
10
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.一项关于唑来膦酸即刻使用与延迟使用预防他莫昔芬治疗后开始来曲唑治疗的绝经后乳腺癌女性骨质流失的随机对照试验的5年随访：N03CC（联盟）试验
Cancer. 2015 Aug 1;121(15):2537-43. doi: 10.1002/cncr.29327. Epub 2015 Apr 30.
引用本文的文献
1
Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis.用于减少早期和局部晚期乳腺癌女性骨丢失的骨修饰剂：一项网络荟萃分析。
Cochrane Database Syst Rev. 2024 Jul 9;7(7):CD013451. doi: 10.1002/14651858.CD013451.pub2.
2
Role of myeloid-derived suppressor cells in tumor recurrence.髓源性抑制细胞在肿瘤复发中的作用。
Cancer Metastasis Rev. 2023 Mar;42(1):113-142. doi: 10.1007/s10555-023-10079-1. Epub 2023 Jan 14.
3
Role of myeloid-derived suppressor cells in metastasis.髓系来源的抑制细胞在转移中的作用。
Cancer Metastasis Rev. 2021 Jun;40(2):391-411. doi: 10.1007/s10555-020-09947-x. Epub 2021 Jan 7.
4
Effectiveness of bisphosphonate combined with activated vitamin D in patients with aromatase inhibitor-induced osteoporosis after breast cancer operation.双膦酸盐联合活性维生素D对乳腺癌术后芳香化酶抑制剂所致骨质疏松患者的疗效
Osteoporos Sarcopenia. 2018 Sep;4(3):102-108. doi: 10.1016/j.afos.2018.08.002. Epub 2018 Sep 7.
5
Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.雌二醇在体外损害唑来膦酸对激素敏感性乳腺癌细胞的抗增殖和促凋亡作用。
PLoS One. 2017 Sep 25;12(9):e0185566. doi: 10.1371/journal.pone.0185566. eCollection 2017.
6
Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.辅助性唑来膦酸在雌激素水平低的乳腺癌患者中的成本效益。
Curr Oncol. 2015 Aug;22(4):e246-53. doi: 10.3747/co.22.2383.
7
Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline.乳腺癌患者的骨骼健康：基于证据的加拿大指南建议
J Clin Med. 2013 Dec 17;2(4):283-301. doi: 10.3390/jcm2040283.
8
Antiresorptive therapy in the management of cancer treatment-induced bone loss.抗吸收疗法在癌症治疗引起的骨质流失管理中的应用
Curr Osteoporos Rep. 2015 Apr;13(2):73-7. doi: 10.1007/s11914-014-0252-x.
9
Bone marrow endothelium-targeted therapeutics for metastatic breast cancer.用于转移性乳腺癌的骨髓内皮靶向治疗药物
J Control Release. 2014 Aug 10;187:22-9. doi: 10.1016/j.jconrel.2014.04.057. Epub 2014 May 10.
10
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer.芳香酶抑制剂相关的骨丢失及其在乳腺癌患者中双磷酸盐的管理。
Breast Cancer (Dove Med Press). 2012 Jun 20;4:91-101. doi: 10.2147/BCTT.S29432.
本文引用的文献
1
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.唑来膦酸立即给药与延迟给药对在他莫昔芬治疗后开始来曲唑治疗的绝经后乳腺癌女性预防骨质流失的作用——N03CC研究
Breast Cancer Res Treat. 2009 Oct;117(3):603-9. doi: 10.1007/s10549-009-0332-2. Epub 2009 Feb 12.
2
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.在乳腺癌辅助芳香化酶抑制剂治疗期间，每月口服伊班膦酸钠预防阿那曲唑引起的骨质流失。
Clin Cancer Res. 2008 Oct 1;14(19):6336-42. doi: 10.1158/1078-0432.CCR-07-5101.
3
FRAX and the assessment of fracture probability in men and women from the UK.FRAX与英国男性和女性骨折概率评估
Osteoporos Int. 2008 Apr;19(4):385-97. doi: 10.1007/s00198-007-0543-5. Epub 2008 Feb 22.
4
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.阿那曲唑与他莫昔芬作为早期乳腺癌辅助治疗的效果：ATAC试验的100个月分析
Lancet Oncol. 2008 Jan;9(1):45-53. doi: 10.1016/S1470-2045(07)70385-6.
5
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.他莫昔芬治疗2 - 3年后依西美坦与他莫昔芬的生存情况及安全性比较（国际依西美坦研究组）：一项随机对照试验
Lancet. 2007 Feb 17;369(9561):559-70. doi: 10.1016/S0140-6736(07)60200-1.
6
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.来曲唑与他莫昔芬作为绝经后内分泌反应性早期乳腺癌女性初始辅助治疗的五年比较：BIG 1-98研究更新
J Clin Oncol. 2007 Feb 10;25(5):486-92. doi: 10.1200/JCO.2006.08.8617. Epub 2007 Jan 2.
7
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.唑来膦酸可抑制早期乳腺癌绝经后女性中芳香化酶抑制剂来曲唑诱导的骨质流失。
J Clin Oncol. 2007 Mar 1;25(7):829-36. doi: 10.1200/JCO.2005.05.3744. Epub 2006 Dec 11.
8
Aromatase inhibitors and bone loss.芳香化酶抑制剂与骨质流失
Oncology (Williston Park). 2006 Aug;20(9):1029-39; discussion 1039-40, 1042, 1048.
9
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).一种芳香化酶抑制剂对骨密度和骨转换标志物的影响：阿那曲唑、他莫昔芬单独或联合使用（ATAC）试验的2年结果（18233230）
J Bone Miner Res. 2006 Aug;21(8):1215-23. doi: 10.1359/jbmr.060508.
10
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.来曲唑与安慰剂对完成5年或更长时间辅助性他莫昔芬治疗的原发性乳腺癌女性骨密度的影响：NCIC CTG MA.17的一项配套研究
J Clin Oncol. 2006 Aug 1;24(22):3629-35. doi: 10.1200/JCO.2005.05.4882. Epub 2006 Jul 5.
Zotero 插件